Insightful Discussions on Acute Agitation
An engaging virtual roundtable hosted by journalist Anjalee Khemlani will delve into recent advancements in treating acute agitation linked to neuropsychiatric conditions. This event, sponsored by BioXcel Therapeutics, brings together distinguished medical experts to shed light on effective self-administered treatments that are changing the landscape of patient care.
Event Details and Expert Insights
This highly anticipated online gathering is set to take place on a Monday morning, gathering healthcare professionals, caregivers, and investors to engage in vital discussions. Participants can look forward to insights from:
- Dr. Leslie Citrome, Clinical Professor of Psychiatry and Behavioral Sciences.
- Dr. Marc A. Milano, Chair of Emergency Medicine.
- Dr. Leon Ravin, Psychiatrist and Statewide Psychiatric Medical Director.
As a noteworthy aspect, they will discuss the rising opportunities and advantages of offering treatments that patients can administer in the comfort of their homes, a significant shift from traditional care settings.
Changing Treatment Paradigms
With millions of agitation episodes reported annually in the home setting for conditions like bipolar disorder and schizophrenia, this roundtable aims to redefine how care is delivered. The discussion will explore innovative solutions that could enhance the management of acute agitation, ensuring that patients receive timely and effective care outside of emergency departments.
Why This Matters to Patients and Caregivers
As the healthcare landscape evolves, this event highlights the crucial need for strategies that empower patients and caregivers. The information shared will pave the way for a deeper understanding of treatment paradigms, focusing on patient-centric approaches that prioritize safety and efficacy.
Attendee Engagement
During the event, attendees will have the opportunity to participate actively by submitting questions through a written Q&A segment. This level of engagement ensures that the discussions remain focused on what matters most to the audience.
About BioXcel Therapeutics
BioXcel Therapeutics, Inc. (NASDAQ: BTAI) is at the forefront of developing innovative treatments in neuroscience, supported by advanced artificial intelligence methodologies. Their approach leverages existing medications and integrates big data along with proprietary algorithms to uncover new therapeutic potentials.
Corporate and Media Contact Information
For investor relations, reach out to Russo Partners. Nic Johnson is available at nic.johnson@russopartnersllc.com or by phone at 1.303.482.6405.
For media inquiries, contact David Schull at david.schull@russopartnersllc.com, with a direct line 1.858.717.2310.
Frequently Asked Questions
What is the purpose of the virtual roundtable?
The roundtable aims to discuss advancements in treatments for acute agitation linked to neuropsychiatric conditions.
Who are the featured speakers?
The event will include insights from Dr. Leslie Citrome, Dr. Marc A. Milano, and Dr. Leon Ravin.
How can I participate in the Q&A?
Attendees can submit their questions during the event via the written Q&A feature.
What is BioXcel Therapeutics' role?
BioXcel Therapeutics sponsors the event and focuses on developing transformative neuroscience medicines using artificial intelligence.
Where can I learn more about the event?
Additional information about the roundtable and its topics will be available on BioXcel Therapeutics' website.
